Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-lin…

The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published

Read more

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — Guardant Health and the National Cancer Center Hospital East will present data

Read more
Show Buttons
Hide Buttons